An interventional study of Probiotic and Placebo in Osteoporosis, Postmenopausal and Bone Density, Low, sponsored by Nordic Biotic Sp. z o.o.. Completed at 3 sites in Poland. Open to female participants. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 34th largest by enrollment, is one of 4 that started in 2022, is one of 2 with no phase, and was the 35th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 543 across the 36 interventional studies. Of the 34 that completed or were terminated, 29 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
Nordic Biotic Sp. z o.o. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Nordic Biotic Sp. z o.o. has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoporosis, Postmenopausal with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Osteoporosis is a systemic condition characterized by low bone mass and altered bone tissue microarchitecture, with the resulting greater bone fragility leading to fractures. Osteoporosis develops as a result of genetic and environmental factors, with the patient's lifestyle playing an important role. Recent years saw an emergence of reports on the significance of the intestinal microbiota in the development of osteoporosis, thus new ways of modifying the composition and activity of microbiota have been sought, and the potential role of probiotics has been considered. Probiotics are defined as live microorganisms, which-when administered at appropriate doses-are beneficial to the host's health. Probiotics both modify the gut microbiota composition and directly affect the human body. Recently published clinical studies demonstrated that probiotics may facilitate osteoporosis treatment and prevention. The current randomized double-blind placebo-controlled study will assess the effect of a dietary intervention via oral supplementation of Lactobacillus plantarum and Lactobacillus paracasei in a population of Polish postmenopausal women on their bone mineral density assessed via bone densitometry-derived T-scores of the lumbar segment of the spine (L1-L4). Study subjects will take the provided probiotic formulation/placebo orally once daily for 12 months.
The main purpose of the study is to assess the effect of oral probiotic supplementation on bone mineral density in postmenopausal women. A total of 170 female subjects who meet all the inclusion criteria and none of the exclusion criteria are to be included and randomized to one of two arms (the probiotic arm or the placebo arm) at a ratio of 1:1.
The subjects who provide their written informed consent will receive oral probiotic formulation containing a mixture of two strains Lactobacillus plantarum and Lactobacillus paracasei or placebo. The probiotic formulation and placebo will be provided by Nordic Biotic Ltd. (the company will also ensure study drug blinding). Study subjects will take the provided probiotic formulation/placebo orally once daily for 12 months.
The study timeline spans 54 weeks and involves 13 visits, including:
All subjects included in the study will undergo:
At each visit, whether conducted at the doctor's office or remotely, subjects will be asked about their use of the study drug and any gastrointestinal symptoms (number of bowel movements, stool consistency, bloating, abdominal pain), and the use of any other medications (including antibiotics). Each time, the subjects will be also asked about any side effects. Stool consistency will be assessed with the Bristol Stool Form Scale, and abdominal pain, bloating, and nausea will be assessed with a 5-grade Likert scale.
Blood samples will be collected from all subjects during the screening period, after 6 months of intervention and at the completion of intervention (i.e. at month 12).
The following blood tests will be conducted:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A dietary supplement in the form of capsules containing probiotic bacterial strains.
Dietary Supplement: Probiotic
Placebo capsules with the same appearance and weight as probiotic capsules.
Other: Placebo
The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).
The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
The effect of intervention on bone mineral density
Bone mineral density (BMD) of the lumbar segment of the spine (L1-L4) will be measured by two densitometry scans (DEXA) and presented as T-score. T-score is measured in standard deviations and reflects the difference between the patient's measured BMD and the mean value of BMD in healthy, young, matched controls (30-year-old women).
Time frame: From baseline and after 12 months of intervention
Changes in the level of calcium
The level of calcium will be measured in serum and expressed in mg/dL.
Time frame: From baseline and after 6 and 12 months of intervention
Changes in the level of phosphorus
The level of phosphorus will be measured in serum and expressed in mg/dL.
Time frame: From baseline and after 6 and 12 months of intervention
Changes in the level of alkaline phosphatase
The level of alkaline phosphatase will be measured in serum and expressed in U/L.
Time frame: From baseline and after 6 and 12 months of intervention
Changes in the level of vitamin D
The level of vitamin D will be measured in serum and expressed in ng/mL.
Time frame: From baseline and after 12 months of intervention
Changes in the level of C-reactive protein
The level of C-reactive protein will be measured in serum and expressed in mg/L.
Time frame: From baseline and after 6 and 12 months of intervention
Changes in Body Mass Index (BMI)
Weight and height will be combined to report BMI in kg/m2.
Time frame: From baseline and after 6 and 12 months of intervention
Changes in type of stools
The stool type will be assessed with the Bristol Stool Formation Scale. The Bristol Stool Formation Scale is designed to classify faeces into seven groups: type 1-2 indicate constipation, type 3-4 are "normal" stools; type 5-7 indicate diarrhea.
Time frame: From baseline for 12 months of intervention in 1 month intervals
Changes in the number of bowel movements
The number of bowel movements per day will be assessed as mean of bowel movements during the last 7 days before visit.
Time frame: From baseline for 12 months of intervention in 1 month intervals
Changes in severity of abdominal pain
The severity of pain will be assessed with a patient-defined 5 point Linkert scale: point 0 - no pain, and 1-4 the severity of pain with higher scores indicating worse pain.
Time frame: From baseline for 12 months of intervention in 1 month intervals
Changes in severity of bloating
The bloating will be assessed with a patient-defined 5 point Linkert scale: point 0 - no bloating, and 1-4 the severity of bloating with higher scores indicating worse bloating.
Time frame: From baseline for 12 months of intervention in 1 month intervals
Occurrence of adverse events
Adverse events will be recorded and described throughout the intervention period
Time frame: For 12 months of intervention in 1 month intervals
Satisfaction with the intervention
Satisfaction with the intervention will be assessed by a questionnaire consisting of 6 questions regarding satisfaction with the form of the preparation, ease of administration, benefits, and course of treatment on a scale of 1-7, with the higher the score, the higher the satisfaction.
Time frame: At months 2, 6, 10, and 12 of the intervention
Plan to share: No
Ran from Mar 2022 to primary completion in Jan 2024, 22 months.
Of 51 interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 22 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
Osteoporosis, Postmenopausal →
Nordic Biotic Sp. z o.o.